Avicanna Inc. (FRA:0NN)

Germany flag Germany · Delayed Price · Currency is EUR
0.144
0.00 (0.00%)
Last updated: Dec 4, 2025, 8:08 AM CET
-33.33%
Market Cap 17.39M
Revenue (ttm) 15.60M
Net Income (ttm) -1.15M
Shares Out n/a
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 19,826
Open 0.144
Previous Close 0.144
Day's Range 0.144 - 0.144
52-Week Range 0.122 - 0.262
Beta n/a
RSI 45.94
Earnings Date Nov 18, 2025

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of de... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Employees 87
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0NN
Full Company Profile

Financial Performance

In 2024, Avicanna's revenue was 25.46 million, an increase of 51.62% compared to the previous year's 16.79 million. Losses were -3.62 million, -58.62% less than in 2023.

Financial numbers in CAD Financial Statements

News

There is no news available yet.